Amgen has posted a 14% decline adjusted net income for the third quarter to $1.31 billion, while turnover was flat at $3.82 billion.
The figures reflect a decline in revenues from its anaemia drug Aranesp (darbepoetin alfa), down 9% to $623 million and its older erythropoiesis stimulating agent, Epogen (epoetin alfa), which slipped 2% to $653 million. Combined turnover of Amgen’s white blood cell stimulators Neulasta (pegfilgrastim) and Neupogen (filgrastim) increased 4% to $1.25 billion, while sales of the anti-inflammatory Enbrel (etanercept), partnered with Pfizer’s Wyeth unit and sold by Amgen in North America, were down 1% at $914 million.
Sensipar (cinacalcet), for the treatment of secondary hyperparathyroidism in dialysis patients, rose 6% to $175 million, while sales of the colorectal cancer drug Vectibix (panitumumab) leapt 21% to $70 million. Nplate (romiplostim), for the treatment of chronic immune thrombocytopenic purpura, increased 94%to $60 million, though analysts were a bit disappointed with sales of Prolia (denosumab).
The latter, which was approved earlier this year in the USA and Europe for the treatment of postmenopausal women at increased risk of osteoporotic fractures, brought in just $10 million. Amgen will find out next month whether the US Food and Drug Administration will back denosumab for the treatment of bone metastases to reduce skeletal related events in patients with cancer, an approval that will boost sales.